Influenza Virus Vaccine 2009-2010 Season

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on February 18, 2009, to select the influenza virus strains for the composition of the influenza vaccine for use in the 2009-2010 U.S. influenza season. During this meeting, the advisory panel reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics, serological responses to 2008/2009 vaccines, and the availability of candidate strains and reagents.

The panel recommended that vaccines to be used in the 2009-2010 influenza season in the U.S. contain the following:

  • an A/Brisbane/59/2007 (H1N1)-like virus; *
  • an A/Brisbane/10/2007 (H3N2)-like virus; **
  • a B/Brisbane/60/2008-like virus.

*A/Brisbane/59/2007 is a current vaccine virus; A/South Dakota/6/2007 (an A/Brisbane/59/2007-like virus) is a current vaccine virus used in live attenuated vaccines.
**A/Brisbane/10/2007 and A/Uruguay/716/2007 (an A/Brisbane/10/2007-like virus) are current vaccine viruses.

The influenza vaccine composition to be used in the 2009-2010 influenza season in the U.S. is identical to that recommended by the World Health Organization on February 12, 2009, for the Northern Hemisphere's 2009-2010 influenza season.

FDA Approves New Influenza Vaccine Production Facility - May 7, 2009

 
Updated: May 7, 2009